Revenue and EBITDA came in ahead, and we reiterate our narrow moat rating and are raising our fair value estimate.
By Neil Macker, CFA | 08-08-17 | 12:15 AM | Email Article

 CBS  posted a slightly better-than-expected second quarter as both revenue and EBITDA came in ahead of expectations. The firm continues to benefit from persistent retrans and reverse comp revenue growth while also profiting from its studio investment via increased content licensing sales. We reiterate our narrow moat rating. We are raising our fair value estimate to $71 from $67 to account for higher retrans and reverse comp revenue as well as the associated margin lift. With the stock trading in 3-star territory, we would wait for a larger margin of safety before investing.

Neil Macker, CFA, is an equity analyst for Morningstar.

Overall revenue was up 9% (excluding the soon to be spun off radio segment) year over year to $3.3 billion. Ad revenue improved by 4% due largely to the NCAA Final Four which drove the 7% increase in network advertising. Affiliate and subscription fees grew 16% year over year as retrans and reverse comp were up 25%. CBS will have all of its retrans and reverse comp deals up for renewal over the next three years, providing the firm with the ability to meet its stated 2020 revenue goal of $2.5 billion. Despite the tough comp from last year’s sale for the international rights to Star Trek library, content licensing and distribution expanded by 12% as management continues to monetize the deep content library. CBS will soon benefit from the first-run syndication of its three third-year shows, NCIS New Orleans, Madam Secretary, and Scorpion, which highlights the firm’s continued investment in its studio. Adjusted operating margin fell by 130 basis points versus a year ago to 20.5% as revenue growth in high margin areas such as retrans and reverse comp were more than offset by increased content costs.

Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.

Securities mentioned in this article



Morningstar Rating Morningstar Analyst Report
With Morningstar Analyst reports you can get our expert Buy/Sell opinions on over 3,900 Stock and Funds
Neil Macker, CFA does not own shares in any of the securities mentioned above. Find out about Morningstar's editorial policies.
Sponsored Links
Sponsor Center
Content Partners